anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a preparation method of a traditional Chinese medicine for treating chest distress type subconjunctival hemorrhage, and belongs to the technical field of preparation methods of traditional Chinese medicines. Currently, sulfonamides and antibiotics are generally adopted to treat chest distress type subconjunctival hemorrhage. A skin test must be preformed before penicillin is used, and penicillin is forbidden if the test result is positive. The preparation method is characterized by comprising the following steps of immersing the following 30 Chinese medicines in water, namely trichosanthes kirilowii maxim, longstamen onion bulb, tangerine seed, tangerine peel, orange, buckeye, tobacco, citron, nutgrass galingale rhizome, mangnolia officinalis, lychee seed, lychee, halite, garden burnet, pink reineckea herb, plant soot, stove, carbonized hair, rumex japonicus, marmor serpentinatum, Chinese arborvitae twig, madder, salvia plebeian, white dead nettle, lithospermum, Japanese beauty-berry, sophora flower, eclipta, rhizoma nelumbinis and liquorice; decocting with slow fire; and filtering and removing slag to obtain decoction, which is the traditional Chinese medicine for treating chest distress type subconjunctival hemorrhage. The traditional Chinese medicine has the advantages of simple manufacture, small toxic and side effect of prepared Chinese medicine decoction, short course of treatment and high cure rate. Monarch, minister, assistant and guide medicines are compatible. Adverse reactions caused by Western medicaments sulfonamides and antibiotics can be avoided.
OBJECTIVE: to assess clinical safety and postoperative audiological outcomes in postlingual deafness Spanish speaking patients, who underwent surgery with Nurotron™ cochlear implant.
MATERIAL AND METHODS: Retrospective descriptive case series study. We performed follow-up of complications and audiological measurements before and after cochlear implantation. Patients with bilateral severe to profound sensorineural hearing loss or patients with unilateral deafness with/without tinnitus were included. Repeated-measures within-subjects for assess pure tone thresholds and speech performance (bilingual test) with a detailed monitoring to establish security or adverse effects were performed. Analysis of variance tests, repetitive measures, were used for statistical analysis.
RESULTS: 31 patients were included, 17 (54.8%) men and 14 (45.2%) women. Mean age at the time of surgery was 49.82 ± 18.8 years. The mean follow-up of the group was 31.56 ± 9.57 months (minimum = 19.6 months and maximum = 52.50 months). As major complication one patient (3.23%) had a hard failure that required removal and re-implantation. 25.8% of the patients presented minor complications, the most frequent being vertigo/unsteadiness in 22.6%. The mean of language discrimination (free field at 65 dB SPL) was 62.19% ± 16.66; being 69.82% ± 7.35 in the group of severe to profound bilateral sensorineural hearing loss. A statistically significant reduction was observed in patients with tinnitus, assessed using the visual analogue scale, preoperative = 7.2 ± 1,6 vs postoperative (18months postoperative) = 1.7 ± 1.3 (p < .001).
CONCLUSIONS: The Nurotron™ cochlear implant shows satisfactory audiological results, in accordance with what has been reported in the literature. Minor complications were similar to previous studies, but the percentage of hard failure should continue to be observed, which was higher than other reports with comparable follow-up.
The study compared two telephone interventions using a four-month longitudinal randomized controlled trial. For the first four weeks, all participants received the same psychoeducation program via telephone. Then for the following four months, eight biweekly telephone follow-up calls were carried out. For these eight follow-up calls, participants were randomized into either one of the two following groups with different conditions. For the Psychoeducation with BA (PsyED-BA) group, participants would receive eight biweekly sessions of BA practice focused on pleasant event scheduling and improving communications. For the Psychoeducation only (PsyED Only) group, there would be eight biweekly sessions of general discussion of psychoeducation and related information
A lotion is, ordinarily, slightly acidic, and moreover has been provided in such three kinds as an acidic lotion, an alkaline lotion, and a neutral lotion. The slight acidic lotion is ordinarily applied as being adapted to pH of skin and not having a particular stimulus thereto. Most of the acidic lotion is applied to make healthy pH of skin which ordinarily tends to become alkaline from Spring to Summer seasons. And alkaline lotion is applied to provide moisture to skin. These conventional types of lotions cause users to less feel moist and do not show an excellent effect of making soft skin. A cosmetic liquid having pH of 9 to 13 is now achieved.
PURPOSE:A skin cosmetic having improved feeling in use free from skin irritation, blending a slightly water-soluble cosmetic component with a cyclodextrin polymer in the form of an inclusion compound of it with the cyclodextrin polymer. CONSTITUTION:A slightly water-soluble cosmetic component (e.g., natural animal or vegetable fats and oils such as olive oil, mink oil, jujube oil, lanolin, hydrocarbon such as liquid paraffin, squalane, etc., wax such as whale wax, bees wax, etc., higher alcohol such as cetanol, etc., higher fatty acid, etc. such as myristic acid, etc., silicone oil, etc.) is blended with a cyclodextrin polymer [having >=20 water-solubility in 100ml water at 25 deg.C; preferably compound shown by the formula (n is 3-4)] in the form of an inclusion compound of it and the cyclodextrin polymer, to give a cosmetic for the skin wherein a large amount of the slightly water-soluble cosmetic component is uniformly blended. The amount of the cosmetic component used is 0.001-0.5pt.wt. based on 1pt.wt. cyclodextrin polymer and the treatment temperature is 10-70 deg.C.
FIELD: biotechnology, medicine. SUBSTANCE: enzymotherapeutic and antiviral preparation is living culture of weak virulent and biochemically active strains of β--hemolytic streptococci of group A in sterile saline solution at concentration 1-2 billion/ml bacterial cells. Method of preparing involves culture mixing with meat-peptone broth and glucose at pH = 7.6-7.8. After flake-like precipitate formation culture is transferred on solid blood agar and incubated. Living culture is removed from blood agar surface by sterile saline solution up to the definite concentration. EFFECT: improved method of preparing.
Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg etarfolatide labeled with 20 to 25 mCi of technetium-99m. Induction phase of treatment: Two 4-week cycles; if stable disease or better at (week 8) computed tomography (CT), participant may proceed into maintenance phase. Maintenance phase of treatment: 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
Disclosed herein is a method and system for evaluating compliance of standard clinical guidelines in medical treatments of one or more patients. Electronic Health Records (EHRs) of the patients are received and aggregated to obtain patient-specific EHRs. Subsequently, the patients are clustered into groups based on disease conditions and socio-demographic characteristics of patients. Further, deviations in the medical treatments provided to the patients are detected by comparing the medical treatments with standard clinical guidelines, for evaluating compliance of the standard clinical guidelines with the medical treatments. In an embodiment, the method of present disclosure helps in detecting care gaps among the medical treatments provided to the patients, and thereby helps in providing improvised and/or patient-specific medical assistance to the patients. Also, the present method is effective in recommending specific amendments and/or improvements to the standard clinical guidelines by detecting nature of deviations in the medical treatments given to the patients.
Skin abscess is one of the most common infections of the skin and soft tissues. However, anaerobic bacteria are infrequently identified as the causative agents of this particular form of abscess. In this case, a 34-year-old pregnant woman was diagnosed with a skin abscess with the use of ultrasonography. The microbiological analysis results of the purulent fluid revealed the coinfection of Actinobaculum schaalii and Actinomyces turicensis. The patient was first treated empirically with 3 days of cefathiamidine, which resulted in no symptom improvement. Subsequently, a surgical procedure involving incision and draining was performed, with the administration of ceftriaxone. After 7 days of antibiotic intervention, the patient exhibited a satisfactory recovery. Clinicians need to be aware of other types of infections that might be attributed to Actinobaculum schaalii and Actinomyces turicensis, in addition to urinary tract infections.
The ketogenic diet (KD) is a popular option for managing body weight, though its influence on glucose and lipid metabolism was still inconclusive. Gut microbiota is modulated by dietary pattens and has been associated with the changes of metabolic homeostasis induced by KD. Here, we found that two types of KDs, KD1 (8.8% carbohydrate, 73.4% fat, 17.9% protein, 5.7 kcal/g) and KD2 (0.4% carbohydrate, 93.2% fat, 6.4% protein, 6.7 kcal/g), induced changes of gut microbiota and its metabolites, contributing to glucose intolerance but not lipid accumulation in mice. Following a 2-week intervention with KDs, mice fed on KD1 displayed symptoms related to obesity, whereas KD2-fed mice exhibited a decrease in body weight but had severe hepatic lipid accumulation and abnormal fatty acid metabolism, while both KDs led to significant glucose intolerance. Compared to the mice fed on a standard chow diet, the conventional mice fed on both KD1 and KD2 had significant shifted gut microbiota, lower levels of short chain fatty acids (SCFAs) and composition alteration of cecal bile acids. By using an antibiotic cocktail (ABX) to deplete most of the gut microbiota in mice, we found the disturbances induced by KDs in lipid metabolism were similar in the ABX-treated mice to their conventional companions, but the disturbances in glucose metabolism were absent in the ABX-treated mice. In conclusion, these findings suggest that ketogenic diets disrupted glucose and lipid metabolism, at least in mice, and highlight the gut microbial culprits associated with KD induced glucose intolerance rather than lipid accumulation.
PURPOSE:To provide the subject protein having an antitumor activity and useful for the therapy of animal epithelial cancer, etc., by extracting the fruit body of Tricholoma matsutake with water, and subsequently successively subjecting the filtrate to a gel filtration column treatment, an anion exchange resin treatment, and a hydrophobic chromatography treatment for the isolation and purification of the protein. CONSTITUTION:The fruit body of Tricholoma matsutake is extracted with water, and the filtrate is subjected to a mol.wt. fractionation treatment with a gel filtration column to purify the protein. The protein is adsorbed to an anion exchange resin, eluted from the column with an eluting agent, further adsorbed onto a resin for hydrophobic chromatography, and again eluted from the column with an eluting agent to provide the pure protein having a mol.wt. of 100000-110000 as its sub unit by a SDS electrophoresis method and a mol.wt. of 200000-210000 by a gel filtration method, exhibiting a pale yellowish brown color to a pale brown color, and having an amino acid composition (molar ratio) of Ser:34.7, Arg:20.1, Asp:15.9, Phe:11.2, Ala:6.3, Thr:2.7, Tyr:2.1, Val:1.8, Ile:1.0, and Lys:0.7, Gly,Cys:0.5.
Homologous recombination is a key process that governs the stability of eukaryotic genomes during DNA replication and repair. Multiple auxiliary factors regulate the choice of homologous recombination pathway in response to different types of replication stress. Using Schizosaccharomyces pombe we have previously suggested the role of DNA translocases Rrp1 and Rrp2, together with Srs2 helicase, in the common synthesis-dependent strand annealing sub-pathway of homologous recombination. Here we show that all three proteins are important for completion of replication after hydroxyurea exposure and provide data comparing the effect of overproduction of Srs2 with Rrp1 and Rrp2. We demonstrate that Srs2 localises to rDNA region and is required for proper replication of rDNA arrays. Upregulation of Srs2 protein levels leads to enhanced replication stress, chromosome instability and viability loss, as previously reported for Rrp1 and Rrp2. Interestingly, our data suggests that dysregulation of Srs2, Rrp1 and Rrp2 protein levels differentially affects checkpoint response: overproduction of Srs2 activates simultaneously DNA damage and replication stress response checkpoints, while cells overproducing Rrp1 mainly launch DNA damage checkpoint. On the other hand, upregulation of Rrp2 primarily leads to replication stress response checkpoint activation. Overall, we propose that Srs2, Rrp1 and Rrp2 have important and at least partially independent functions in the maintenance of distinct difficult to replicate regions of the genome.
This phase 2/3 open-label trial is being conducted at approximately 100 sites in the US to assess the safety and tolerability of long-term treatment with lacosamide (SPM 927) in subjects with painful diabetic neuropathy. Approximately 525 subjects will be enrolled. To qualify for this trial, subjects with symptoms of painful distal diabetic neuropathy ranging in duration from 6 months to 5 years must have completed trials SP665, SP742, or SP768 and, in the investigator's opinion, may benefit from long-term administration of lacosamide. Subjects will be titrated to their optimal dose of lacosamide (up to 600mg/day). The safety and tolerability of the different doses of lacosamide will be investigated throughout the trial. In addition, to determine what effect lacosamide has on diabetic neuropathic pain, subjects will use a diary to record their daily pain intensity and pain interference with sleep and activity. Subjects' quality of life will also be investigated.
Group B: Up to 30 healthy volunteers 65 plus years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
Participants will be asked to consume 180 mg/day of stevia (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 800 mg/day of stevia (or about 12 cans of stevia-sweetened diet soda).
A fructus phyllanthi pit aided lead elimination health food/drug comprises fructus phyllanthi, organic calcium, cereal grains and edible sugar. According to the weight ratio, the fructus phyllanthi is 45-60g, the organic calcium is 15-25g, the cereal grains (starch) are 35-45g, and the edible sugar is 5-15g. The weight ratio of the components is selected according to the above range. Preparing steps include: firstly using high-quality fructus phyllanthi as a raw material and then cleaning the fructus phyllanthi with clear water; drying; subjecting the dried raw material to microwave treatment; accurately weighing the raw materials according to the weight ratio and then mixing and crushing the raw materials; and using a pelletizer to pelletize the materials to obtain a finished product. The fructus phyllanthi pit aided lead elimination health food/drug is capable of supplying eight types of amino acids and nutrients necessary to human bodies, nutrient collocation is reasonable, the nutrients ingested by human bodies are more balanced and reasonable, and optimization of a dietary structure is achieved for people. The fructus phyllanthi pit aided lead elimination health food/drug has effects of pressure decrease, fat reduction and refreshing, is widely suitable for young and old, has no side effects and can be eaten every day.
FIELD: cosmetic industry, medicine. SUBSTANCE: an agent has sodium chloride and hydrocarbonate and zeolite-containing addition. The latter - clinoptilolite sodium form or zeolite-containing addition modified with copper, zinc or silver ions taken at amount 0.01-1.0 wt.-% and zeolite has particle size 0.01-100 mcm. Invention can be used as a prophylactic agent for skin care and its deep cleaning from ammonia, calcium, cesium and other heavy metal ions including radioactive isotopes and for skin cleaning before the use of cosmetic nutrient creams, pastes and lotions and this agent shows a bactericidal and softening effect additionally. The agent is an ecologically safety preparation that ensures to clean human skin from harmful ions and no causing allergy. EFFECT: improved quality and properties, enhanced effectiveness of an agent. 5 cl, 5 ex
Participants receive placebo in session 1 and placebo in session 2 of a psychological stressor presentation and receive placebo in session 1 and placebo in session 2 of a physiological stressor presentation. Participants take placebo tablets for 7 days prior to each session. The placebo group is used for analysis purposes in order to control for any order effects found in the Experimental group.
Methylprednisolone(ivMP) 500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
Safety during long-term use for more than 2 years at the doses required for parkinsonism has not been established.

As with any chronic therapy, periodic evaluation of hepatic, hematopoietic, cardiovascular, and renal function is recommended. Symptomatic hypotension can occur and, therefore, caution should be exercised when treating patients receiving antihypertensive drugs.

High doses of bromocriptine may be associated with confusion and mental disturbances. Since parkinsonian patients may manifest mild degrees of dementia, caution should be used when treating such patients.

Bromocriptine administered alone or concomitantly with levodopa may cause hallucinations (visual or auditory). Hallucinations usually resolve with dosage reduction; occasionally, discontinuation of bromocriptine is required. Rarely, after high doses, hallucinations have persisted for several weeks following discontinuation of bromocriptine.

As with levodopa, caution should be exercised when administering bromocriptine to patients with a history of myocardial infarction who have a residual atrial, nodal, or ventricular arrhythmia.

Retroperitoneal fibrosis has been reported in a few patients receiving long-term therapy (2 to 10 years) with bromocriptine mesylate in doses ranging from 30 to 140 mg daily.
The first intervention trial will enroll 9 participants (3 participants per site). Exit interviews of participants will assess acceptability, feasibility, and relevance of the intervention. Quantitative assessments pre and post intervention using audio computer-assisted self-interviewing (ACASI) will document immediate changes in substance use, sexual risk, and adherence to medical care. Additional qualitative feedback from interviews with mental health providers and study coordinators will address feasibility, acceptability, and relevance of the intervention and its methods.
Parkinson's Disease (PD) is a severe neurological movement disorder comprising the triad of symptoms of bradykinesia, rigidity and tremor. It can be effectively treated with dopaminergic replacement therapy in the early course of the disease; however, after 5-10 years medical therapy is insufficient in the majority of patients. Since the early 90s the implantation of electrodes into the Nucleus subthalamicus (STN), (deep brain stimulation; DBS) has been established. DBS in PD- patients provides a definite and longlasting relief of motor symptoms and impaired quality of life compared to optimized medical treatment (Deuschl et al. 2006). Conventionally, electrodes are implanted into STN but other targets such as the pedunculopontine nucleus or the Zona incerta (ZI) have been reported to be useful. Importantly, the ZI has a key role in connection loops from the basal ganglia, thalamic regions and cortex. Retrospective studies of DBS-treated patients show relief of symptoms in DBS- treated PD patients, with the contacts of the electrodes being located to the ZI (Voges et al., 2002; Hamel et al., 2003a, 2003b). However, no prospective randomized studies analysing the effect of bilateral DBS comparing the targets of the caudal ZI (cZI) and STN are available. Therefore, the present study will investigate the effect and tolerance of DBS in both targets in a blind, randomized and stratified design in a total of 70 PD patients (see below for inclusion end exclusion criteria). The impairment of movement and quality of life will be assessed via established scales. Effects, tolerance and side effects of DBS will be monitored closely and re-assessed for a period of twelve months. Primary study criteria include UPDRS-III and quality of life.
Within each of up to 5 treatment periods, 2 participants were randomly assigned to receive single oral doses of matching placebo in a fasted stated. There was to be a minimum 7-day washout between treatment periods for any given participant.
Patients randomized into the Zometa arm received a total of 8 study drug infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.